U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
Contact Us FAQs Site Map About MedelinePlus
español
HealthDay Logo

Sepsis Therapy in Preemies Fails to Boost Survival

Study suggests future treatments should focus on wider view of antibacterial defenses
Printer-friendly version E-mail this page to a friend

HealthDay

By Kevin McKeever

Friday, January 16, 2009

HealthDay news imageFRIDAY, Jan. 16 (HealthDay News) -- Boosting the immune systems of premature babies with blood cell growth factor fails to prevent sepsis or improve survival rates, a new study shows.

Premature babies, especially those with lower than normal birth weight, tend to be prone to infections from low white blood cell counts. Blood growth factors, such as granulocyte-macrophage colony stimulating factor (GM-CSF), increase white blood cell counts and are often used in cancer patients to counter immune suppression caused by chemotherapy.

The London-based study, published in the current issue of The Lancet, found giving GM-CSF to premature babies with low birth weight did increase their white counts but, when compared with preterms who did not receive the treatment, they did not have lower rates of infection or better survival rates.

"We believe that, before embarking on future single-agent clinical trials, we should consider if this is too simplistic an approach to sepsis prevention in the preterm infant, whose immune system appears compromised in many different ways. ... Successful future stratagems will need a wider view of their antibacterial defenses," wrote the authors, lead by Robert Carr of Guy's and St Thomas Hospital NHS Trust in London.


HealthDay

Copyright (c) 2009 ScoutNews, LLC. All rights reserved.

Related News:
More News on this Date

Related MedlinePlus Pages: